Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Oncogenic osteomalacia 2Nevus, Sebaceous of Jadassohn 2

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × burosumab × Clear all
NCT02304367 2024-05-06

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
17 enrolled 66 charts

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

NCT02722798 2022-09-06

A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

Kyowa Kirin Co., Ltd.

Phase 2 Completed
14 enrolled

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡